Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Immune & inflammatory · 2026

Lisraya (brepocitinib)

The FDA approved Lisraya (brepocitinib) on August 27, 2026 to treat dermatomyositis in adults.
Brand name
Lisraya
Generic name
brepocitinib
FDA approval date
August 27, 2026
Approved use (FDA wording)
To treat dermatomyositis in adults
Company
Priovant Therap
Application
NDA220106
Dosage form / route
TABLET · ORAL
Boxed warning on label
Yes (see the FDA label)
Category on this site
Immune & inflammatory

Indications and usage, from the FDA label

LISRAYA is indicated for the treatment of dermatomyositis in adult patients. LISRAYA is a Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of dermatomyositis in adult patients. ( 1 ) Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs. Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.